Tavolimab

Tavolimab
Monoclonal antibody
Type ?
Source Chimeric/humanized hybrid (mouse/human)
Target CD134
Clinical data
Synonyms MEDI0562
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6508H10026N1730O2032S42
Molar mass 146.4 g/mol

Tavolimab (MEDI0562, formerly tavolixizumab) (INN[1]) is a chimeric/humanized monoclonal antibody designed for the treatment of cancer.

This drug is being developed by MedImmune.[2]

References

  1. ↑ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
  2. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Tavolimab, American Medical Association.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.